Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

被引：0
|
作者：
Enrico Tiacci
Luca De Carolis
Edoardo Simonetti
Mara Merluzzi
Antonio Bennati
Vincenzo Maria Perriello
Alessandra Pucciarini
Alessia Santi
Alessandra Venanzi
Valentina Pettirossi
Gianluca Schiavoni
Luisa Tasselli
Stefano Ascani
Stefano Volpetti
Brunangelo Falini
机构：
[1] University and Hospital of Perugia,Hematology
[2] University of Perugia and Hospital of Terni,Anatomic Pathology
[3] Azienda Sanitaria Universitaria Integrata,Clinica Ematologica
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3314 / 3318
页数：4
相关论文
共 50 条
  • [21] Efficacy and Safety of AP0866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial
    Goldinger, Simone M.
    Bischof, Sharon Gobbi
    Fink-Puches, Regina
    Klemke, Claus-Detlev
    Dreno, Brigitte
    Bagot, Martine
    Dummer, Reinhard
    JAMA DERMATOLOGY, 2016, 152 (07) : 837 - 839
  • [22] Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia
    Kuruvilla, Denison
    Chia, Yen Lin
    Balic, Kemal
    Yao, Nai Shun
    Kreitman, Robert J.
    Pastan, Ira
    Li, Xia
    Standifer, Nathan
    Liang, Meina
    Tseng, Chih-Ming
    Faggioni, Raffaella
    Roskos, Lorin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (07) : 1367 - 1376
  • [23] Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436)
    不详
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (10) : 1189 - 1189
  • [24] SAFETY AND EFFICACY OF THE BRUTON TYROSINE KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA: INTERIM RESULTS OF A PHASE 2 STUDY
    Jones, J. A.
    Andritsos, L.
    Ravandi, F.
    Kreitman, R. J.
    Schiffer, C.
    Call, T.
    Lozanski, G.
    Sexton, J.
    Harris, P.
    Grever, M. R.
    HAEMATOLOGICA, 2015, 100 : 313 - 313
  • [25] Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
    Carmen F. Nobre
    Matthew J. Newman
    Anne DeLisa
    Pauline Newman
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 255 - 263
  • [26] Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
    Nobre, Carmen F.
    Newman, Matthew J.
    DeLisa, Anne
    Newman, Pauline
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 255 - 263
  • [27] Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)
    Kreitman, Robert J.
    Moreau, Philippe
    Hutchings, Martin
    Gazzah, Anas
    Blay, Jean-Yves
    Wainberg, Zev A.
    Stein, Alexander
    Dietrich, Sascha
    de Jonge, Maja J. A.
    Willenbacher, Wolfgang
    De Greve, Jacques
    Arons, Evgeny
    Ravandi, Farhad
    Rangwala, Fatima
    Burgess, Paul
    Mookerjee, Bijoyesh
    Subbiah, Vivek
    BLOOD, 2018, 132
  • [28] PHASE-II CLINICAL-TRIAL OF CARBOPLATIN IN RELAPSED AND REFRACTORY LEUKEMIA
    VOGLER, WR
    HARRINGTON, DP
    WINTON, EF
    LAZARUS, HM
    BENNETT, JM
    CASSILETH, PA
    OKEN, MM
    LEUKEMIA, 1992, 6 (10) : 1072 - 1075
  • [29] SAFETY AND ACTIVITY OF BLINATUMOMAB IN TWO PHASE-2 TRIALS IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY B-PRECURSOR ACUTE LYMBOBLASTIC LEUKEMIA
    Grande Garcia, C.
    Kantarjian Hagop, M.
    Stein, A. S.
    Bargou Ralf, C.
    Larson, R. A.
    Stelljes, M.
    Benjamin, J.
    Jia, C.
    Topp Max, S.
    HAEMATOLOGICA, 2015, 100 : 19 - 19
  • [30] Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
    Daver, Naval
    Lee, Kyoo Hyung
    Choi, Yunsuk
    Jonas, Brian A.
    Arellano, Martha
    Koller, Paul B.
    Jung, Chul W.
    Sohn, Sang Kyun
    Fathi, Amir T.
    Lee, Jeong-Ok
    Yoon, Sung-Soo
    Watts, Justin M.
    Vachhani, Pankit
    Shin, Ho-Jin
    Hu, Jia
    Sinha, Ranjeet
    Khan, Nawazish
    Rice, William G.
    Bejar, Rafael
    BLOOD, 2023, 142
12345